Cite
Metabolic models predict fotemustine and the combination of eflornithine/rifamycin and adapalene/cannabidiol for the treatment of gliomas.
MLA
Kishk, Ali, et al. “Metabolic Models Predict Fotemustine and the Combination of Eflornithine/Rifamycin and Adapalene/Cannabidiol for the Treatment of Gliomas.” Briefings in Bioinformatics, vol. 25, no. 3, May 2024, pp. 1–15. EBSCOhost, https://doi.org/10.1093/bib/bbae199.
APA
Kishk, A., Pacheco, M. P., Heurtaux, T., & Sauter, T. (2024). Metabolic models predict fotemustine and the combination of eflornithine/rifamycin and adapalene/cannabidiol for the treatment of gliomas. Briefings in Bioinformatics, 25(3), 1–15. https://doi.org/10.1093/bib/bbae199
Chicago
Kishk, Ali, Maria Pires Pacheco, Tony Heurtaux, and Thomas Sauter. 2024. “Metabolic Models Predict Fotemustine and the Combination of Eflornithine/Rifamycin and Adapalene/Cannabidiol for the Treatment of Gliomas.” Briefings in Bioinformatics 25 (3): 1–15. doi:10.1093/bib/bbae199.